Clinical Trials Directory

Trials / Conditions / Recurrent Colorectal Carcinoma

Recurrent Colorectal Carcinoma

22 registered clinical trials studyying Recurrent Colorectal Carcinoma — 3 currently recruiting.

StatusTrialSponsorPhase
WithdrawnPembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
NCT05518032
Roswell Park Cancer InstitutePhase 2
Not Yet RecruitingMolecular Study and Precision Medicine for Colorectal Cancer
NCT05883683
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology—
SuspendedFluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Co
NCT06307548
Roswell Park Cancer InstitutePhase 1 / Phase 2
RecruitingImmune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
NCT06349642
Mayo Clinic—
Active Not RecruitingLY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastat
NCT04616183
M.D. Anderson Cancer CenterPhase 1 / Phase 2
Active Not RecruitingEncorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unres
NCT04017650
M.D. Anderson Cancer CenterPhase 1 / Phase 2
UnknownComparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia
NCT03823079
Fudan UniversityPhase 2
CompletedCelecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metast
NCT03403634
Roswell Park Cancer InstitutePhase 2
CompletedCapecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colo
NCT02873195
Academic and Community Cancer Research UnitedPhase 2
CompletedPembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
NCT03095781
Emory UniversityPhase 1
CompletedAPN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid
NCT03087591
Wake Forest University Health SciencesPhase 1
TerminatedLiver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be R
NCT02738606
M.D. Anderson Cancer CenterPhase 2
CompletedCetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Remove
NCT02713373
Roswell Park Cancer InstitutePhase 1 / Phase 2
TerminatedFOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
NCT02508077
City of Hope Medical CenterPhase 2
TerminatedTLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Pro
NCT02650635
Mayo ClinicPhase 1
CompletedPhase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas
NCT02973672
SurgimabPhase 1 / Phase 2
Active Not RecruitingTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph
NCT02465060
National Cancer Institute (NCI)Phase 2
CompletedSelumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorec
NCT02188264
National Cancer Institute (NCI)Phase 1
CompletedRomidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun
NCT01638533
National Cancer Institute (NCI)Phase 1
CompletedVaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
NCT01522820
Roswell Park Cancer InstitutePhase 1
RecruitingAssociation Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and
NCT01365169
M.D. Anderson Cancer CenterN/A
CompletedSafety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinom
NCT00545545
HiberCell, Inc.Phase 1 / Phase 2